These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38372710)

  • 21. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.
    Li X; Cesta A; Movahedi M; Bombardier C
    Arthritis Res Ther; 2022 Nov; 24(1):255. PubMed ID: 36401335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.
    Versteeg GA; Steunebrink LMM; Vonkeman HE; Ten Klooster PM; van der Bijl AE; van de Laar MAFJ
    Clin Rheumatol; 2018 May; 37(5):1189-1197. PubMed ID: 29388086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
    PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
    Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
    Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI).
    Pope JE; Rampakakis E; Movahedi M; Cesta A; Sampalis JS; Bombardier C;
    Rheumatology (Oxford); 2021 Feb; 60(2):717-727. PubMed ID: 32789456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Druce KL; Bhattacharya Y; Jones GT; Macfarlane GJ; Basu N
    Rheumatology (Oxford); 2016 Oct; 55(10):1786-90. PubMed ID: 27330158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study.
    Lee J; Mason R; Martin L; Barnabe C
    Rheumatol Int; 2014 Oct; 34(10):1449-53. PubMed ID: 24682439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
    Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
    J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis.
    Yu C; Li M; Duan X; Fang Y; Li Q; Wu R; Liu S; Wang Y; Wu Z; Shi X; Jiang Z; Wang Y; Hsieh ED; Jin S; Jiang N; Wang Q; Zhao Y; Tian X; Zeng X;
    Clin Exp Rheumatol; 2018; 36(5):836-840. PubMed ID: 29600939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study.
    Pope JE; Rampakakis E; Sampalis J
    Semin Arthritis Rheum; 2015 Apr; 44(5):499-505. PubMed ID: 25440158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?
    Marks JL; Holroyd CR; Dimitrov BD; Armstrong RD; Calogeras A; Cooper C; Davidson BK; Dennison EM; Harvey NC; Edwards CJ
    Arthritis Care Res (Hoboken); 2015 May; 67(6):746-53. PubMed ID: 25605045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
    Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M
    Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative.
    Ruban TN; Jacob B; Pope JE; Keystone EC; Bombardier C; Kuriya B
    Clin Rheumatol; 2016 Mar; 35(3):759-63. PubMed ID: 26245721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
    Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
    Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
    Mease PJ; Stryker S; Liu M; Salim B; Rebello S; Gharaibeh M; Collier DH
    Arthritis Res Ther; 2021 Sep; 23(1):236. PubMed ID: 34496952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.